ALURD · Allurion Technologies, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations, and noncompliance with certain financial covenants under its credit facilities, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued.”View the 10-Q filed May 15, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $12.6M | $15.23MG | $32.11MG | $53.47M | |
| $5.96M | $5.66M | $10.61M | $11.97M | |
| $6.64M | $9.57M | $21.5M | $41.5M | |
| — | 62.84% | 66.97% | 77.61% | |
| $5.86M | $7.57M | $17.37M | $27.69M | |
| $8.49M | $10.8M | $25.93M | $46.86M | |
| $18.9M | $21.35M | $28.4M | $46.02M | |
| $951K | $983K | $997K | $746K | |
| — | — | $3.9M | $1M | |
| $33.25M | $39.73M | $71.7M | $120.58M | |
| -$26.61M | -$30.16M | -$50.2M | -$79.08M | |
| — | -198.01% | -156.33% | -147.9% | |
| -$25.66M | -$29.17M | -$49.2M | -$78.33M | |
| — | $0 | $2.26M | $10.57M | |
| -$6.74M | $1.48M | $43.72M | -$3.48M | |
| -$33.35M | -$28.68M | -$6.48M | -$82.55M | |
| $1000 | $74K | $718K | $264K | |
| -$33.35M | -$28.76M | -$7.2M | -$82.82M | |
| — | -188.8% | -22.42% | -154.89% | |
| — | — | -$7.2M | -$84.51M | |
| -$23.29M | -$15.25M | -$16.27M | -$82.12M | |
| USD/shares | — | -$57.15 | -$48.00 | -$890.70 |
| USD/shares | — | -$57.15 | -$48.00 | -$890.70 |
| shares | — | 502.97K | 149.81K | 94.89K |
| shares | — | 502.97K | 149.81K | 94.89K |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 76 similar-size Medical Devices companies (of 145 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| All Other Countries | $11,235,000 | $25,415,000 | $35,078,000 | $42,240,000 |
| Spain | $2,154,000 | $4,008,000 | $4,618,000 | $6,852,000 |
| Italy | $1,841,000 | $2,687,000 | — | — |
| Chile | — | — | $2,708,000 | $5,008,000 |
| France | — | — | $5,569,000 | $6,032,000 |
| TRY | — | — | $5,494,000 | $4,079,000 |